Dendreon Corporation Cancer Drugs Clinical Pipeline Insight

Publish Date:- Nov-2016       No Of Pages (27)

Electronic Access - Single User License $500 Buy Now
CD-ROM Mail Delivery $800Buy Now
Hard Copy Mail Delivery $800 Buy Now
Electronic Access - Multi-User License $1000 Buy Now


“Dendreon Corporation - Cancer Drugs Clinical Pipeline Insight” offers in depth insight on ongoing clinical trials for the cancer drugs developed by Dendreon Corporation. This report highlights various clinical and non-clinical parameters involved in the development of cancer drugs in clinical pipeline. Currently there is “1” cancer drug in clinical pipeline. There is 1 cancer drug by Dendreon Corporation which is commercially available in the market.

The report includes all the relevant information with respect to development of cancer drugs in the clinical pipeline. Report helps the reader in identifying various data and information points like Drug Class, Mechanism of Action, Granted Orphan Designation, Fast Track Development Status, Clinical Introduction, Drug Formulation/ Route, Owner/License, Multiple Development Phase of particular drug and Patent Information.

“Dendreon Corporation - Cancer Drugs Clinical Pipeline Insight” report is comprehensively researched and well drafted encyclopedia which helps to analyze and understand the various parameters involved in the clinical development of cancer drugs by the respective company. This research publication also helps in identifying the long term investment and partnering opportunity for the various stake holders of the pharmaceutical industry.


“Dendreon Corporation - Cancer Drugs Clinical Pipeline Insight” offers in depth insight on ongoing clinical trials for the cancer drugs developed by Dendreon Corporation. This report highlights various clinical and non-clinical parameters involved in the development of cancer drugs in clinical pipeline. Currently there is “1” cancer drug in clinical pipeline. There is 1 cancer drug by Dendreon Corporation which is commercially available in the market.

The report includes all the relevant information with respect to development of cancer drugs in the clinical pipeline. Report helps the reader in identifying various data and information points like Drug Class, Mechanism of Action, Granted Orphan Designation, Fast Track Development Status, Clinical Introduction, Drug Formulation/ Route, Owner/License, Multiple Development Phase of particular drug and Patent Information.

“Dendreon Corporation - Cancer Drugs Clinical Pipeline Insight” report is comprehensively researched and well drafted encyclopedia which helps to analyze and understand the various parameters involved in the clinical development of cancer drugs by the respective company. This research publication also helps in identifying the long term investment and partnering opportunity for the various stake holders of the pharmaceutical industry.

1. Dendreon Corporation

  1.1 Business Overview

  1.2 Dendreon Corporation Cancer Pipeline Overview

 

2. Dendreon Corporation Cancer Drugs in Phase-II

  2.1 Lapuleucel-T

 

3. Marketed Cancer Drugs by Dendreon

  3.1 Sipuleucel (Provenge)

 

4. Discontinued in Cancer Drugs in Clinical Pipeline

  4.1 Recombinant NAPc2

  4.2 APC 8020

  4.3 CTL 8004

  4.4 Matriptase Inhibitors - Amgen/Dendreon

  4.5 Endotheliase Inhibitors - Dendreon/Dyax

  4.6 DN 1924

  4.7 Cancer Vaccine NY-ESO-1 – Dendreon

  4.8 Protease Activated Cancer Therapy – Dendreon

  4.9 Urokinase Plasminogen Activator Inhibitors – Dendreon

 

5. Suspended in Cancer Drugs in Clinical Pipeline

  5.1 D 3263

  5.2 Anti-CA9 Vaccine – Dendreon

  5.3 Anti-CEA Vaccine – Dendreon


Figure 1-1: Dendreon Corporation Cancer Pipeline by Phase (%)

Figure 1-2: Dendreon Corporation Cancer Pipeline by Phase (Number)

Figure 1-3: Dendreon Corporation Cancer Drugs Discontinued & Suspended in Clinical Pipeline by Phase (%)

Figure 1-4: Dendreon Corporation Cancer Drugs Discontinued & Suspended in Clinical Pipeline by Phase (Number)